Fair Value - Additional Information (Details) $ / shares in Units, $ in Thousands	1 Months Ended		3 Months Ended		12 Months Ended
	Sep. 30, 2020	Jan. 31, 2016 USD ($) shares	Mar. 31, 2021 USD ($) $ / shares shares	Mar. 31, 2020 USD ($)	Dec. 31, 2018 USD ($) Installment shares	Feb. 28, 2018 USD ($) shares
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Change in contingent consideration			$ 983	$ 957
Put option liability				2,000
Warrants, expires period			Feb. 23, 2028
Estimated air value of warrants issued			$ 300
Change in fair value of warrant liability				$ 51
Initial Public Offering
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant, exercise price | $ / shares			$ 4.46
Warrant issued to purchase shares | shares			103,326
Series F Preferred Stock
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent value rights shares | shares		3,999
Contingent value rights		$ 500
Contingent value rights percentage		0.00375%
Net proceeds percentage of cash payment to the CVR holders		15.00%
Series F Preferred Stock | AVEO Oncology
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Percentage of development and regulatory costs exercised using opt-out right	50.00%
2018 Notes
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Estimated air value of warrants issued						$ 300
2018 Notes | Series G Preferred Stock
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant issued to purchase shares | shares			613,333			613,333
Warrant, exercise price | $ / shares			$ 0.75
Integrated Diagnostics, Inc
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business acquisition description			requires additional consideration to be paid by the Company to Indi upon attainment of a three-consecutive month
Business acquisition contingent consideration gross margin target					$ 2,000
Business acquisition contingent consideration gross margin target period					7 years
Integrated Diagnostics, Inc | Common Stock
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business acquisition description			If Indi elects to not exercise its option, the Company has 12 months to repurchase the common stock in two equal and consecutive quarterly cash installments totaling $37.0 million.
Contingent consideration shares | shares					2,520,108
Contingent consideration number of installments | Installment					8
Contingent consideration arrangements, common shares, redemption amount					$ 37,000
Integrated Diagnostics, Inc | Common Stock | Repurchase
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration number of installments | Installment					2
Contingent consideration cash payment					$ 37,000
Minimum
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Percentage of probabilities of contingent consideration successful achievement of specified product gross margin targets discount rates range			12.20%
Maximum
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Percentage of probabilities of contingent consideration successful achievement of specified product gross margin targets discount rates range			13.50%